Please use this identifier to cite or link to this item: http://hdl.handle.net/11434/1985
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAbeyakoon, Chathuri-
dc.contributor.authorHarrop, Sean-
dc.contributor.authorYannakou, Costas-
dc.contributor.authorPrince, Miles-
dc.contributor.othervan der Weyden, Carrie-
dc.contributor.otherKhot, Amit-
dc.contributor.otherDickinson, Michael-
dc.date2021-01-22-
dc.date.accessioned2021-06-10T04:20:31Z-
dc.date.available2021-06-10T04:20:31Z-
dc.date.issued2021-06-
dc.identifier.citationVolume 21, Issue 6, June 2021, Pages 368-378en_US
dc.identifier.issn2152-2650en_US
dc.identifier.urihttp://hdl.handle.net/11434/1985-
dc.description.abstractPeripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphomas that are frequently associated with a poor prognosis. For many decades, the standard-of-care has been CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone)-based therapy, but it is well-recognized that survival outcomes are unsatisfactory, especially when compared with B-cell lymphomas. Major recent advances in cancer diagnosis and management have the potential to significantly improve PTCL outcomes. These include: (1) improved diagnostic techniques that incorporate molecular genetic data to further refine diagnosis and subtyping; (2) the development of novel agents; and (3) improved monitoring modalities, such as <sup>18</sup>F-fluorodeoxyglucose positron emission tomography-computed tomography scans and circulating tumor DNA. In this review, we aim to explore these 3 advances in the context of frontline management of PTCL.en_US
dc.publisherElsevieren_US
dc.subjectDisease Monitoringen_US
dc.subjectHematopoietic Stem Cell Transplantationen_US
dc.subjectMolecular Diagnosticsen_US
dc.subjectNovel Agentsen_US
dc.subjectRadiotherapyen_US
dc.subjectDepartment of Haematology, Epworth HealthCare, Melbourne, Victoria, Australiaen_US
dc.subjectCancer Services Clinical Institute, Epworth HealthCare, Victoria, Australiaen_US
dc.titleAdvances in frontline management of peripheral T-cell lymphoma.en_US
dc.typeJournal Articleen_US
dc.identifier.doi10.1016/j.clml.2021.01.012en_US
dc.identifier.journaltitleClinical Lymphoma, Myeloma & Leukemiaen_US
dc.description.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/33610499/en_US
dc.description.affiliatesDepartment of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australiaen_US
dc.description.affiliatesSir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australiaen_US
dc.description.affiliatesDepartment of Haematology, Royal Melbourne Hospital, Melbourne, Victoria, Australiaen_US
dc.type.studyortrialReviewen_US
dc.type.contenttypeTexten_US
Appears in Collections:Cancer Services

Files in This Item:
There are no files associated with this item.


Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.